Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma

The development of BRAF and MEK inhibitors (BRAFi/MEKi) has led to major advances in melanoma treatment. However, the emergence of resistance mechanisms limits the benefit duration and a complete response occurs in less than 20% of patients receiving BRAFi ± MEKi. In this study, we evaluated the imp...

全面介紹

Na minha lista:
書目詳細資料
發表在:Transl Oncol
Main Authors: Reger de Moura, Coralie, Vercellino, Laetitia, Jouenne, Fanélie, Baroudjian, Barouyr, Sadoux, Aurélie, Louveau, Baptiste, Delyon, Julie, Serror, Kevin, Goldwirt, Lauriane, Merlet, Pascal, Bouquet, Fanny, Battistella, Maxime, Lebbé, Céleste, Mourah, Samia
格式: Artigo
語言:Inglês
出版: Neoplasia Press 2019
主題:
Original article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6931208/
https://ncbi.nlm.nih.gov/pubmed/31874374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2019.10.003
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍